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MaOBJECTIVES The goal of this study was to compare regadenoson and dipyridamole hyperemia for quantitative
myocardial perfusion imaging.
BACKGROUND Regadenoson is commonly used for stress perfusion imaging. However, no study in nuclear cardiology
has employed a paired design to compare quantitative hyperemic ﬂow from regadenoson to more traditional agents such
as dipyridamole. Additionally, the timing of regadenoson bolus relative to tracer administration can be expected to affect
quantitative ﬂow.
METHODS Subjects underwent 2 rest/stress cardiac positron emission tomography scans using an Rb-82 generator.
Each scan employed dipyridamole and a second drug in random sequence, either regadenoson according to 5 timing
sequences or repeated dipyridamole. A validated retention model quantiﬁed absolute ﬂow and coronary ﬂow reserve.
RESULTS A total of 176 pairs compared regadenoson (126 pairs, split unevenly among 5 timing sequences) or repeated
dipyridamole (50 pairs). The cohort largely had few symptoms, only risk factors, and nearly normal relative uptake
images, with 8% typical angina or dyspnea, 20% manifest coronary artery disease, and a minimum quadrant average
of 80% (interquartile range: 76% to 83%) on dipyridamole scans. Hyperemic ﬂow varied among regadenoson timing
sequences but showed consistently lower stress ﬂow and coronary ﬂow reserve compared with dipyridamole. A timing
sequence most similar to the regadenoson package insert achieved about 80% of dipyridamole hyperemia, whereas
further delaying radiotracer injection reached approximately 90% of dipyridamole hyperemia. Because of the small
numbers of pairs for each regadenoson timing protocol and a paucity of moderate or large perfusion defects, we did not
observe a difference in relative uptake.
CONCLUSIONS With the standard timing protocol from the package insert, regadenoson achieved only 80% of
dipyridamole hyperemia quantitatively imaged by cardiac positron emission tomography using Rb-82. A nonstandard
protocol using a more delayed radionuclide injection after the regadenoson bolus improved its effect to 90% of dipyr-
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AB BR E V I A T I O N S
AND ACRONYM S
ANOVA = analysis of variance
CFR = coronary ﬂow reserve
CT = computed tomography
FFR = fractional ﬂow reserve
IQR = interquartile range
LV = left ventricle/ventricular
PET = positron emission
tomography
PRP = pressure–rate product
SPECT = single-photon
emission computed
tomography
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439bridging or coronary anomalies). Because the vast
majority of dynamic coronary disease can be treated
medically, vasodilator stress offers a more speciﬁc
tool for identifying patients who may beneﬁt from
revascularization of signiﬁcant ﬁxed disease.
After the ﬁrst vasodilator stress imaging in 1978
with dipyridamole (2), it became widely available by
1995 (3) and adenosine by 1994 (4). A decade later,
adenosine A2A receptor agonists were developed like
binodenoson in 2004 (5), regadenoson in 2005 (6),
and apadenoson around that time (NCT00990327),
although currently only regadenoson has regulatory
approval. Although dipyridamole, adenosine, and
regadenoson offer tradeoffs in terms of cost, infusion
duration, and side-effect proﬁle, the key diagnostic
question remains the degree of hyperemia. A lesser
hyperemic stimulus underestimates physiologic ste-
nosis severity.SEE PAGE 448Currently, regadenoson enjoys its largest market for
myocardial perfusion imaging. Existing studies in this
area comparing it with established vasodilators have
never employed a paired design with absolute ﬂow
quantiﬁcation. Therefore, we used cardiac positron
emission tomography (PET) to compare the degree of
hyperemia between regadenoson and dipyridamole.
Additionally, we explored the timing effect of radio-
tracer injection following the regadenoson bolus.
METHODS
We performed an investigator-initiated, single-cen-
ter, diagnostic accuracy study at the Weatherhead
PET Center for Preventing and Reversing Athero-
sclerosis of the University of Texas Medical School at
Houston and Memorial Hermann Hospital. Subjects
gave written informed consent as approved by the
institutional review board and underwent enrollment
between December 2012 and June 2014.
Subjects at least 40 years or older were recruited
by convenience via several routes: volunteers not
meeting entry criteria for our ongoing randomized
Century trial (NCT00756379), patients referred for a
clinical study whose insurance denied approval, our
own clinic patients, and word of mouth. Exclusion
criteria included any absolute contraindication to
dipyridamole or regadenoson, pregnancy or active
breastfeeding, current participation in another clin-
ical research study, and inability to undergo 2 PET
scans within 2 months, but at least 1 day apart.
Subjects were instructed not to change medications
or have invasive procedures between the 2 PET
scans.The vast majority of subjects received 2
different vasodilators. Assignment of subjects
to drug sequence (dipyridamole then regade-
noson, or regadenoson then dipyridamole)
was performed by the nuclear medicine
technologist at the time of the ﬁrst PET scan
by using a coin ﬂip for 1:1 randomization.
Investigators, study subjects, and PET center
staff performing imaging were not blinded to
vasodilator assignment. A minority of sub-
jects received dipyridamole for both scans to
quantify its test/retest repeatability. Eleven
subjects could not complete both scans and
were excluded from the analysis. To screen
for drugs that might affect vasodilation,
serum and urine samples at each PET scan were
tested for caffeine, nicotine, and nicotine’s metabo-
lite cotinine.
A sample size of about 50 complete pairs was
estimated based on a paired t test with a ¼ 0.05, b ¼
0.80, variance in stress ﬂow of 0.37 to 0.50, variance
in CFR of 0.80 to 0.94 (both derived from our pre-
vious work), and the desire to detect differences
between 0.2 and 0.5 in stress ﬂow and CFR. After
completely enrolling and analyzing this ﬁrst timing
sequence, we decided to study additional timing
sequences to construct a response curve. Each
timing sequence had a pre-speciﬁed sample size
based on the variance observed in the ﬁrst
sequence. Therefore, our study consisted of serial
mini-trials, each performed and primarily analyzed
separately.
CARDIAC PET ACQUISITION AND ANALYSIS. Our
imaging protocol has been described previously, and
this section follows previous publications closely (7).
Subjects were instructed to fast for 4 h and abstain
from caffeine, theophylline, and cigarettes for 24 h.
Cardiac PET was performed using a Discovery ST
16-slice PET-CT scanner (GE Healthcare, Waukesha,
Wisconsin) in 2-dimensional mode with settings for
an in-plane resolution of approximately 6 to 7 mm
full-width at half-maximum.
Rest emission images were obtained over 7 min
beginning immediately upon intravenous injection of
30 to 50 mCi of generator-produced Rb-82 (Bracco
Diagnostics, Princeton, New Jersey). The ﬁrst 2 min
during emission were binned to form the arterial
input image. The last 5 min during emission were
binned to form the myocardial uptake image. After
completion of the resting scan, pharmacological
stress was performed as detailed in the following
text, and the same dose of radiotracer was injected.
Stress emission images were acquired for 7 min and
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440binned into arterial and myocardial images as for the
resting scan.
Severe angina relieved only after intravenous
aminophylline or theophylline, sublingual nitroglyc-
erin, and/or intravenous metoprolol was noted,
distinct from common and nonischemic vasodilator-
induced chest symptoms treated routinely with
xanthine derivatives. Continuous 12-lead electro-
cardiographic monitoring during stress identiﬁed
signiﬁcant, >1-mm ST-segment depression. Hemo-
dynamic parameters of heart rate and blood pressure
were recorded at the time of both tracer injections.
Computed tomography (CT) scans for attenuation
correction were acquired before rest and after stress
emission imaging and have been previously reported
(8). Fusion images superimposed PET emission and
CT transmission scans in horizontal, coronal, and
sagittal views. Coregistration was optimized by shift-
ing as needed. PET images were reconstructed using
ﬁltered back-projection with a ramp ﬁlter (cutoff
6.5 mm) and then post-processed by a ﬁfth-order
Butterworth ﬁlter (cutoff 0.50 cycles/cm). After
attenuation correction and reconstruction, transaxial
PET images were exported for analysis on CARDIAC
software (version 4.66, Positron Corporation, West-
mont, Illinois) to generate true short- and long-axis
views, perpendicular and parallel to the long axis
of the left ventricle (LV). Circumferential proﬁles of
maximum radial activity for each true short-axis slice
were used to construct 2-dimensional topographic
views of the LV.
Four basal slices were not used for quantitative
analysis because of low counts in the membranous
interventricular septum. Two apical slices were not
used for quantitative analysis because of potential
partial volume errors and apical motion. Combined
size and severity of perfusion defects was quantiﬁed
by 2 metrics: ﬁrst, the percentage of the LV with
relative activity <60% of maximum activity (100%),
which is >6 SD below mean activity in normal vol-
unteers (7); and, second, the value in the quadrant
with the lowest average relative uptake (minimum
quadrant average).
For each radial segment of every short-axis slice,
our experimentally validated model (9) implemented
using commercial software (10) quantiﬁed absolute
myocardial ﬂow. The ﬂow model does not use time-
activity curves, but instead, integrates arterial input
and myocardial uptake over the ﬁrst 2 and next 5 min,
respectively, after tracer injection. Our ﬂow model
has also been used by others (11), who reported it
to “have higher sensitivity for detection and locali-
zation of abnormal ﬂow” (12) than time-activity curve
models (13) that we consider less suited for routineclinical application, as in our daily practice for
over 7 years.
The topographic map of absolute ﬂow was
smoothed using a 5-by-5 pixel average to suppress
imaging noise. CFR was computed as the stress-
to-rest ratio on a pixel basis. We employ the term
CFR instead of myocardial ﬂow reserve to emphasize
the general physiological principle independent of
measurement technique. Arterial inputs were cus-
tomized from among the aortic and left atrium loca-
tions as previously detailed (14).
VASODILATOR STRESS PROTOCOLS. Dipyridamole
(142 mg/kg/min) was infused for 4 min. Four min after
the completion of dipyridamole infusion, the Rb-82
generator was activated.
Figure 1 displays the 5 different regadenoson
timing protocols. The sequence of Rb-82 generator
activation, radiotracer delivery, and PET scanner
imaging remained the same in all cases. However, the
temporal difference between the regadenoson bolus
and Rb-82 generator activation varied. A single-use,
pre-ﬁlled, 5-ml syringe of regadenoson 0.4 mg was
administered as a 10-s injection via peripheral vein,
followed by a 5-ml ﬂush.
Timing protocol B in Figure 1 corresponds to the
package insert instructions to “administer the radio-
nuclide myocardial perfusion imaging agent 10 to 20 s
after the saline ﬂush” (15). Note that the name for
protocol B in other ﬁgures and tables as þ10 s refers
to the time from starting the regadenoson bolus to
activating the Rb-82 generator. Although the exact
radiotracer delivery start time after activation varied
slightly among generators, typically it took approxi-
mately 10 to 15 s to begin.
STATISTICAL ANALYSIS. We used R version 3.1.0
(R Foundation for Statistical Computing, Vienna,
Austria) and employed standard summary statistical
tests. Applicable tests were 2-tailed, and p < 0.05 was
considered statistically signiﬁcant. Minimum quad-
rant average and percentage of the LV below 60%
of maximum were found to be sufﬁciently non-
normal on inspection of quantile–quantile plots.
Analysis of variance (ANOVA) compared characteris-
tics among the timing protocols. Paired t tests or
Wilcoxon signed rank tests compared ﬂow and uptake
endpoints between scans in the same subject. A
McNemar test compared binary regadenoson and
dipyridamole effects.
An ANOVA model with mixed effects (to account
for repeated measurements from the same subject)
compared absolute ﬂow and CFR among the 5 re-
gadenoson timing sequences (15, þ10, þ40, þ55,
and þ80 s). If an overall ANOVA p value was
FIGURE 1 Regadenoson Timing Protocols
Image Arterial Phase
Infuse
Bolus
Regadenoson
Rb-82 Generator
PET Scanner
Activate
About -15 Seconds
Image
Myocardial
Phase
A
Regadenoson
Rb-82 Generator
PET Scanner
+10 Seconds
B
Regadenoson
Rb-82 Generator
PET Scanner
+40 Seconds
C
Regadenoson
Rb-82 Generator
PET Scanner
+55 Seconds
D
Regadenoson
Rb-82 Generator
PET Scanner
+80 Seconds
E
(A–E) Each row represents a different timing sequence, depicting time along the x-axis for 3 different components: regadenoson administration
(top line), Rb-82 generator activation and radiotracer infusion (teal dot along middle line), and positron emission tomography (PET) imaging
(bottom line). Thick black lines denote activity on the thin gray timelines. The regadenoson bolus lasted 10 s for all protocols, followed by a 5-ml
saline ﬂush. Typically, 10 to 15 s elapsed between generator activation and radiotracer injection, here denoted as a ﬁxed 15-s interval. PET imaging
began coincident with radiotracer infusion and occurred in 2 sequential components: a 2-min arterial phase followed immediately by a 5-min
myocardial phase. Thepink arrowand text for each sequence gives the time between starting the regadenoson bolus and activating the generator.
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TABLE 1 Cohort Cha
Demographics
Pairs
Age (yrs)
Male
Body mass index (kg
Risk factors and history
Hypertension
Dyslipidemia
Diabetes mellitus
Tobacco (current or
Previous invasive ang
Previous PCI
Previous CABG
Previous MI
Medications
Statin
Antiplatelet
Beta-blocker
ACE-I or ARB
Calcium blocker
Diuretic
Nitrate
Symptoms and EF
Typical angina
Dyspnea
LVEF (%)
Dipyridamole hemodyn
Rest heart rate (beat
Rest systolic blood p
Rest diastolic blood
Stress heart rate (be
Stress systolic blood
Stress diastolic blood
2nd drug (repeat dipyr
Rest heart rate (beat
Rest systolic blood p
Rest diastolic blood
Stress heart rate (be
Stress systolic blood
Stress diastolic blood
Values are n, mean  SD,
ACE-I ¼ angiotensin-con
MI ¼ myocardial infarction
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442signiﬁcant, then a Tukey all-pair comparison was
applied to determine which conditions provided a
different response. To explore for a potential differ-
ential effect of body mass index on absolute ﬂow or
CFR, we employed a mixed-effects ANOVA model
with an interaction term between body mass index
and the pharmacological stressor. To explore for ef-
fect of the pressure–rate product (PRP) on absolute
ﬂow or CFR, we employed a mixed-effects ANOVAracteristics
All Pairs
Repeat
Dipyridamole
Regadenoson
15 s
Regad
þ
176 50 15 5
60  9 62  10 64  8 57
126 (72) 38 (76) 12 (80) 35
/m2) 28  5 28  5 27  5 28
79 (45) 22 (44) 10 (67) 20
132 (75) 40 (80) 10 (67) 34
15 (9) 7 (14) 3 (20) 3
previous) 52 (30) 16 (32) 3 (20) 17
iography 37 (21) 12 (24) 4 (27) 9
27 (15) 8 (16) 5 (33) 7
8 (5) 3 (6) 2 (13) 2
16 (9) 4 (8) 3 (20) 4
88 (50) 25 (50) 10 (67) 23
84 (48) 17 (34) 9 (60) 27
49 (28) 15 (30) 8 (53) 10
48 (27) 14 (28) 3 (20) 12
14 (8) 3 (6) 1 (7) 4
22 (12) 7 (14) 3 (20) 4
3 (2) 1 (2) 0 (0) 1
3 (2) 1 (2) 0 (0) 2
10 (6) 2 (4) 0 (0) 3
73  8 72  8 70  10 73
amics
s/min) 63  11 61  10 60  10 64
ressure (mm Hg) 115  17 119  19 117  16 113
pressure (mm Hg) 66  10 68  10 63  10 64
ats/min) 89  13 87  13 83  13 91
pressure (mm Hg) 119  15 122  17 111  15 117
pressure (mm Hg) 63  10 64  9 57  12 62
idamole or regadenoson) hemodynamics
s/min) 63  12 60  10 59  8 65
ressure (mm Hg) 117  17 117  15 116  18 117
pressure (mm Hg) 67  11 67  9 63  9 66
ats/min) 91  15 85  15 82  12 96
pressure (mm Hg) 120  19 120  14 111  18 120
pressure (mm Hg) 62  12 64  10 61  14 60
or n (%).
verting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery by
; PCI ¼ percutaneous coronary intervention.model that adjusted for its value at rest, hyperemia,
and CFR (both).
RESULTS
Table 1 lists the clinical and hemodynamic charac-
teristics of the participants with complete pairs. The
median time between scans was 14 (interquartile
range [IQR]: 7 to 21) days. Eleven additional subjectsenoson
10 s
Regadenoson
þ40 s
Regadenoson
þ55 s
Regadenoson
þ80 s
p
Value
0 15 31 15 NA
 10 61  7 60  10 58  6 0.042
(70) 13 (87) 16 (52) 12 (80) 0.13
 5 30  4 28  5 31  6 0.29
(40) 7 (47) 14 (45) 6 (40) 0.63
(68) 14 (93) 24 (77) 10 (67) 0.30
(6) 1 (7) 1 (3) 0 (0) 0.21
(34) 5 (33) 9 (29) 2 (13) 0.68
(18) 5 (33) 4 (13) 3 (20) 0.60
(14) 3 (20) 1 (3) 3 (20) 0.11
(4) 0 (0) 1 (3) 0 (0) 0.60
(8) 2 (13) 2 (6) 1 (7) 0.69
(46) 11 (73) 15 (48) 4 (27) 0.13
(54) 8 (53) 17 (55) 6 (40) 0.25
(20) 5 (33) 7 (23) 4 (27) 0.22
(24) 7 (47) 9 (29) 3 (20) 0.60
(8) 2 (13) 4 (13) 0 (0) 0.69
(8) 3 (20) 4 (13) 1 (7) 0.66
(2) 1 (7) 0 (0) 0 (0) 0.69
(4) 0 (0) 0 (0) 0 (0) 0.91
(6) 2 (13) 2 (6) 1 (7) 0.68
 7 69  8 76  5 75  8 0.031
 11 64  13 65  12 66  14 0.35
 16 114  15 115  16 112  12 0.60
 9 67  14 64  12 68  6 0.33
 13 92  13 91  13 93  15 0.15
 15 121  13 120  15 120  14 0.21
 9 65  14 64  11 63  8 0.21
 13 61  9 67  12 68  15 0.023
 18 116  24 117  13 117  14 1.00
 13 68  14 67  9 70  10 0.68
 15 88  11 98  14 93  13 <0.001
 22 114  21 124  19 122  18 0.30
 14 62  14 62  11 63  9 0.66
pass graft surgery; EF ¼ ejection fraction; LVEF ¼ left ventricular ejection fraction;
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443were excluded because they only completed 1 PET
scan for a variety of reasons: 6 had a severe clinical
event or invasive procedure, 2 were unable to obtain
intravenous access, 1 had bronchospasm from dipyr-
idamole (successfully treated by aminophylline
alone), and 2 had scheduling issues. Absolute rest and
stress heart rates for regadenoson or repeat dipyr-
idamole differed among the timing groups (p ¼ 0.023
and p < 0.001, respectively). However, relative heart
rate and blood pressure changes between rest and
stress showed no signiﬁcant differences among the
various timing groups.
Figure 2 and Table 2 provide the absolute ﬂow
and CFR results. Resting ﬂow did not vary between
repeated dipyridamole scans or between dipyrida-
mole and regadenoson under any timing protocol.
However, stress ﬂow and CFR were systematically
lower for all regadenoson timing sequences but un-
changed for repeat dipyridamole. The relationship
between absolute stress ﬂow and CFR versus timing
sequence in Figure 2 demonstrates a rise/fall pattern
such that stress ﬂow and CFR were highest for
the þ55 s protocol (Rb-82 generator activated 55 s after
the start—not end—of the 10 s regadenoson bolus).
Mixed-effects ANOVA demonstrated no signiﬁcant
difference in resting ﬂow among the 5 regadenoson
timing sequences (p ¼ 0.12), whereas signiﬁcant dif-
ferences were noted for stress ﬂow and CFR (both
p < 0.001). The Tukey comparison demonstrated
that regadenoson stress ﬂow was lower than dipyri-
damole for the 15, þ10, and þ40 s timing sequences
(all p # 0.002), with nonsigniﬁcant trends for
the þ55 and þ80 s timing sequences (p ¼ 0.16 andFIGURE 2 Absolute Flow and Coronary Flow Reserve
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(A to C) Each panel depicts the unitless ﬂow ratio to baseline dipyridamo
correspond to the red text in Figure 1) and repeated dipyridamole (Dipy
summarize the mean, and the thin pink bars mark 1 SD.p ¼ 0.082, respectively). Stress ﬂow was higher for
the þ55 sequence compared with 15 or þ10 (both p #
0.002), higher for þ80 compared with 15 (p ¼ 0.007),
and borderline for þ40 compared with 15 (p ¼
0.081). Similarly, the Tukey comparison found that
regadenoson CFR was lower than dipyridamole for
the 15, þ10, and þ55 timing sequences (p < 0.001)
and borderline for þ40 and þ80 (p ¼ 0.079 and p ¼
0.104, respectively). CFR was higher for the þ40, þ55,
and þ80 sequences compared with 15 (all p # 0.021).
No signiﬁcant differential effect of body mass in-
dex on absolute ﬂow or CFR was observed between
regadenoson and dipyridamole (all p > 0.05 for an
interaction). Rest PRP and dipyridamole ﬂow were
signiﬁcantly, but weakly, correlated (r2 ¼ 0.21; p <
0.001), as were stress PRP and dipyridamole ﬂow
(r2 ¼ 0.15; p < 0.001), implying that PRP explains
about 20% or less of the population variation in ﬂow.
The ﬁndings in Table 2 did not change signiﬁcantly
after adjusting for PRP. Injected Rb-82 dose did
not differ systematically between dipyridamole and
regadenoson (paired p > 0.99).
Overall, the cohort mostly demonstrated nearly
normal stress images, with a median 0.4% (IQR: 0%
to 2.3%) of the LV below 60% of maximum and min-
imum quadrant average of 80% (IQR: 76% to 83%)
on dipyridamole scans. Consequently, each timing
sequence contained very few abnormal scans. Taken
together, these circumstances explain why paired
comparisons for both relative uptake metrics showed
no signiﬁcant differences between dipyridamole or
regadenoson for any timing sequence, despite a
difference in the magnitude of hyperemia.ega
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TABLE 2 Absolute Flow and CFR
Pairs
Absolute Flow (ml/min/g) or CFR D (Compared With Baseline Dipyridamole) p Value (Paired t Test)
Rest Stress CFR Rest Stress CFR Rest Stress CFR
Dipyridamole (all) NA 0.85  0.25 2.27  0.57 2.80  0.65 NA NA
Repeat dipyridamole 50 0.81  0.24 2.19  0.61 2.80  0.59 0.02  0.17 0.09  0.39 0.07  0.48 0.46 0.13 0.29
Regadenoson 15 s 15 0.76  0.17 1.34  0.36 1.77  0.37 0.01  0.16 0.59  0.37 0.76  0.67 0.76 <0.001 0.001
Regadenoson þ10 s 50 0.83  0.26 1.79  0.44 2.26  0.45 0.02  0.22 0.44  0.42 0.62  0.54 0.55 <0.001 <0.001
Regadenoson þ40 s 15 0.76  0.16 1.84  0.45 2.50  0.45 0.02  0.13 0.31  0.25 0.38  0.54 0.57 <0.001 0.016
Regadenoson þ55 s 31 1.04  0.32 2.33  0.57 2.36  0.52 0.05  0.17 0.21  0.33 0.36  0.65 0.10 0.001 0.004
Regadenoson þ80 s 15 0.91  0.29 2.21  0.47 2.55  0.56 0.02  0.20 0.30  0.42 0.39  0.31 0.76 0.016 <0.001
Values are mean  SD.
CFR ¼ coronary ﬂow reserve.
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detected 7 subjects with caffeine on both scans, 9
subjects with nicotine or cotinine on both scans, 13
subjects with caffeine on only 1 scan, 12 subjects
with tobacco on only 1 scan, and 1 subject with
caffeine on only 1 scan, but with cotinine on both
scans. Serum caffeine levels were low, median 1.6
mg/l (IQR: 1.3 to 1.9 mg/l), as were tobacco tests for
urine nicotine, median 14 ng/ml (IQR: 4 to 120 ng/ml),
and cotinine, median 24 ng/ml (IQR: 4 to 182 ng/ml).
Our results did not differ in any signiﬁcant fashion
after excluding the 21 pairs with detectable caffeine
at either study.
In the 5 subjects with caffeine on only 1 scan who
underwent repeat dipyridamole testing, stress ﬂow
was signiﬁcantly reduced by caffeine (D ¼ 0.67; 95%
conﬁdence interval 0.17 to 1.18 ml/min/g; p ¼ 0.021),
and CFR demonstrated a downward trend (D ¼ 0.52;
95% conﬁdence interval 0.14 to 1.17; p ¼ 0.09). Only
3 subjects had tobacco on only 1 scan who under-
went repeat dipyridamole testing, and differences
for stress ﬂow and CFR were not signiﬁcant.
Of the 3 patients who had severe angina during
vasodilation, 2 occurred with dipyridamole, but only
1 with regadenoson (p ¼ 1.0 by McNemar). Of the 6
patients who had signiﬁcant ST-segment depression
during vasodilation, 5 occurred with dipyridamole,
but only 1 with regadenoson (p ¼ 0.22 by McNemar).
No patient had severe angina or signiﬁcant ST-
segment depression with both vasodilators, even
after excluding pairs with detected serum caffeine.
DISCUSSION
Our paired study comparing regadenoson to dipyr-
idamole hyperemia for cardiac PET imaging demon-
strated that regadenoson used per the package
insert (15) achieved approximately 80% of absolute
stress ﬂow and CFR. As expected from basic phar-
macological and physiological principles, the timingof radiotracer injection after the regadenoson bolus
affected the degree of observed hyperemia. Acti-
vating the Rb-82 generator 55 s after beginning the
regadenoson bolus improved the result to about
90% of dipyridamole hyperemia.
A large number of published reports supports the
clinical utility of quantifying ﬂow using cardiac PET,
as we have summarized recently (16). Global CFR
can stratify prognosis, quantifying the net effect of
risk factors, microvascular disease, epicardial focal
and diffuse atherosclerosis, and even noncoronary
diseases such as aortic stenosis. For clinicians and
researchers using cardiac PET, the inferior hyper-
emia provided by regadenoson blunts the beneﬁts
of quantifying absolute ﬂow and CFR.
Clearly, the timing of the regadenoson bolus
relative to radiotracer injection must inﬂuence the
quantiﬁed stress ﬂow and therefore CFR. Unlike
intracoronary pressure and ﬂow sensors that allow
for continuous readings, nuclear imaging requires
comparatively much longer acquisition periods in
addition to the time for tracer circulation and uptake.
During the development of regadenoson, data re-
garding bolus timing came from intracoronary ﬂow
sensors in animal models as well as a small number
of humans. However, these surrogates for radiotracer
kinetics and associated ﬂow quantiﬁcation provide a
suboptimal guide for timing a radionuclide injection,
given several factors not accounted for by instanta-
neous pressure and ﬂow wire measurements (delay
and dispersion by venous and lung transit and cardiac
output; and time-dependent myocardial extraction).
Our much more extensive exploration of bolus
timing suggests that the existing regadenoson pack-
age insert (15) should be revised because it pro-
vides only about 80% of dipyridamole hyperemia
for cardiac PET. Instead of the current recommenda-
tion to “administer the radionuclide myocardial
perfusion imaging agent 10–20 seconds after the sa-
line ﬂush” (15), our data favor a 50- to 60-s delay after
TABLE 3 Review of Existing Published Reports
First Author (Ref. #) Comparison Paired? Flow? N Summary
PET
Cullom et al. (18) Dipyridamole Yes No 32 No ﬂow, same uptake
Bravo et al. (19) Dipyridamole No Yes 57 Same ﬂow
Goudarzi et al. (20) Dipyridamole No Yes 104 Same ﬂow
Current study Dipyridamole Yes Yes 126 Inferior ﬂow
SPECT
Hendel et al. (6) Adenosine Yes No 36 No ﬂow, same uptake
Iskandrian et al. (21) Adenosine Yes No 517 No ﬂow, same uptake
CMR
Vasu et al. (22) Both Yes Yes 15 Similar ﬂow
DiBella et al. (23) Adenosine Yes Semi 28 Same ﬂow
FFR
Arumugham et al. (24) Adenosine Yes No 20 D ¼ 0.004  0.025
Nair et al. (25) Adenosine Yes No 25 D ¼ 0.003  0.016
Prasad et al. (26) Adenosine Yes No 57 D ¼ 0.002  0.025
van Nunen et al. (27) Adenosine Yes No 100 D ¼ <0.01  0.01
CMR ¼ cardiac magnetic resonance; FFR ¼ fractional ﬂow reserve; PET ¼ positron emission tomography;
Semi ¼ semiquantitative; SPECT ¼ single-photon emission computed tomography.
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445the saline ﬂush. The trend in Figure 2 could be
extended and made more granular to identify the
bolus timing (or timings, if a plateau period exists)
associated with the highest average hyperemia.
Because of the scintigraphic imaging technique and
immeasurable individual patient factors like cardiac
output and regadenoson pharmacodynamics, optimal
bolus timing in nuclear cardiology can realistically
only be a group average.
Despite giving explicit instructions before the PET
scan and asking detailed questions at the time of each
visit to exclude noncompliance, we still detected re-
sidual serum caffeine in 8% of cases and evidence of
tobacco in 9%. Caffeine is well known to blunt hy-
peremia, as conﬁrmed in our “natural history” sub-
group of patients with and without caffeine on paired
dipyridamole studies. Similarly, tobacco also reduces
hyperemia (7), although we did not see this effect in
our small, paired subgroup. Discovering residual
serum caffeine in 8% of cases in this study was
smaller than 15% in a cohort of young, normal vol-
unteers (7) and 19% in a clinical population (17).
Together, these ﬁndings suggest that routine caffeine
screening may be necessary in addition to patient in-
structions and questioning, especially when quanti-
fying absolute ﬂow.
Intriguingly, dipyridamole produced more severe
angina (2 vs. 1) and signiﬁcant ST-segment depression
(5 vs. 1) than regadenoson, although these ﬁndings
are limited by very small sample sizes. Further work
could explore the suggested hypothesis that the
longer duration and superior vasodilatory potency of
dipyridamole compared with regadenoson more often
provokes these diagnostically important clinical and
electrocardiographic responses.
COMPARISON TO EXISTING PUBLISHED REPORTS. Rega-
denoson has been compared in humans to adeno-
sine or dipyridamole in 4 general settings: PET
imaging; single-photon emission computed tomog-
raphy (SPECT) imaging; cardiac magnetic resonance
imaging; and intracoronary FFR. Table 3 summarizes
the existing literature across these categories com-
pared with the current study, with an emphasis on
important details like ﬂow quantiﬁcation, sample
size, and paired versus unpaired designs (6,18–27). A
few aspects deserve special comment.
No previous PET study has both quantiﬁed abso-
lute ﬂow and used a paired design. Relative uptake
defects by PET using summed stress and difference
scores found no difference between paired regade-
noson and dipyridamole (18), but did not quantify
ﬂow. Absolute ﬂow did not differ between unpaired
cohorts that received regadenoson and dipyridamole(20). However, a paired design augments the ability to
detect a difference between groups, likely explaining
the discordance between their ﬁndings and ours.
A large study found no signiﬁcant difference in
SPECT defects using paired regadenoson and adeno-
sine (21). Similar to our study, their clinical popula-
tion was largely normal, with only 9% demonstrating
a large reversible defect. Differing from our study,
SPECT did not quantify absolute ﬂow or employ
attenuation correction, and it has an inherently
lower spatial resolution than PET. Therefore, these
results are likely consistent with our observation of
a reduction in absolute stress ﬂow and CFR.
A prior cardiac magnetic resonance study com-
pared absolute ﬂow among regadenoson, dipyr-
idamole, and adenosine, with 15 normal volunteers
receiving all 3 vasodilators (22). Interestingly, they
also used a longer delay between the regadenoson
bolus and tracer injection of 70 s, similar to our
ﬁndings in Figure 2, but without explanation or sys-
tematic exploration of the effect of bolus timing.
However, unlike our results, they found that rega-
denoson provided superior stress ﬂow compared with
dipyridamole or adenosine (3.58  0.58 ml/min/g vs.
2.81  0.67 ml/min/g and 2.78  0.61 ml/min/g,
respectively) with similar ordering for CFR (3.11 
0.62 vs. 2.61  0.57 and 2.7  0.30, respectively).
Several potential explanations exist, notably the
much smaller sample size and different imaging mo-
dality compared with our cohort.
FFR shows excellent agreement between regade-
noson and adenosine, with no signiﬁcant bias and
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
timing of rubidium-82 radiotracer administration after
a regadenoson bolus affects the magnitude of absolute
stress ﬂow and CFR as quantiﬁed by cardiac PET.
COMPETENCY IN PATIENT CARE: Activating the
rubidium-82 generator approximately 55 s after the
start of the regadenoson bolus increases absolute
stress ﬂow and CFR to 90% of dipyridamole levels,
compared to only 80% when using the timing in-
structions from the package insert.
TRANSLATIONAL OUTLOOK: Hyperemic agents
for perfusion imaging require a systematic and quan-
titative analysis of their timing characteristics in rela-
tion to the magnitude of stress ﬂow and CFR. Future
studies could look at regadenoson in more detail, or
examine other common agents like adenosine and
dipyridamole.
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surements using the same vasodilator. Therefore,
instantaneous hyperemia after regadenoson bolus
appears to reach the same peak level as during
adenosine infusion. However, the duration of the
hyperemic plateau demonstrates great heterogeneity
among individuals: 14% <30 s, 26% <60 s, and
65% <3 min (27). The variation in hyperemic duration
from the instantaneous FFR data supports our
observed group reduction in absolute stress ﬂow and
CFR, especially when accounting for added hetero-
geneity of radiotracer transit times from intravenous
injection until reaching the coronary arteries and
time-dependent myocardial uptake of radionuclide.
STUDY LIMITATIONS. Our design did not blind the
physician, patient, or nuclear medicine technologist
to the vasodilator, or use a blinded core lab. However,
we randomized the order of regadenoson and dipyr-
idamole and used standard, objective, approved
software packages for image processing and quanti-
tative analysis, including ﬂow measurements. We
employed the recommended 10 s injection of rega-
denoson. Future studies could explore hemodynamic
and ﬂow responses when altering this duration.
Dipyridamole served as our reference vasodilator
instead of adenosine, reﬂecting our own clinical
practice and likely a majority of other cardiac PET
centers. The equivalence between the 2 agents for
cardiac PET has been explored in several previous
studies, mainly showing similar hyperemia. There-
fore, we surmise that results would also hold when
comparing regadenoson to adenosine.
Our cohort included few patients with moderate or
large defects. We suspect, but can only hypothesize,
that relative uptake equivalence may not hold for this
subset. Indeed, our results indicate that ﬂow quanti-
ﬁcation enables detection of signiﬁcant effects with a
smaller sample size that relative uptake images—a
point worth emphasizing for phase 1 and 2 and
diagnostic accuracy trials. Finally, we did not ex-
plore whether the clinical decisions resulting from
regadenoson versus dipyridamole would lead to
signiﬁcantly different long-term patient outcomesbecause of the low risk, predominantly normal or
only mild relative uptake defects in our study
population.
CONCLUSIONS
When administered per the standard timing protocol
of the package insert (15), regadenoson achieved only
80% of dipyridamole hyperemia quantitatively im-
aged by cardiac PET with Rb-82. Delaying radionu-
clide injection further after the regadenoson bolus
improved its hyperemia to around 90% of dipyr-
idamole levels.
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